News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
550,200 Results
Type
Article (40089)
Company Profile (108)
Press Release (510003)
Section
Business (154331)
Career Advice (2452)
Deals (28083)
Drug Delivery (101)
Drug Development (73292)
Employer Resources (141)
FDA (13664)
Job Trends (12287)
News (274615)
Policy (27222)
Tag
2024 BioCapital Digital (1)
2024 BioForest Digital (5)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (1)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (8)
2024 Biotech Beach Digital (3)
2024 Biotech Beach Standard (3)
2024 Genetown Standard (2)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (3)
2024 Pharm Country Standard (3)
2025 Lone Star Bio Digital (1)
2026 BioCapital Elite (1)
2026 BioMidwest Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (1)
Academia (2556)
Academic (1)
Accelerated approval (2)
Adcomms (26)
Allergies (72)
Alliances (39159)
ALS (83)
Alzheimer's disease (1364)
Antibody-drug conjugate (ADC) (116)
Approvals (13658)
Artificial intelligence (214)
Autoimmune disease (16)
Automation (14)
Bankruptcy (311)
Best Places to Work (10020)
BIOSECURE Act (15)
Biosimilars (87)
Biotechnology (86)
Bladder cancer (58)
Brain cancer (24)
Breast cancer (231)
Cancer (1848)
Cardiovascular disease (157)
Career advice (2058)
Career pathing (31)
CAR-T (133)
Cell therapy (365)
Cervical cancer (14)
Clinical research (59466)
Collaboration (656)
Compensation (249)
Complete response letters (21)
COVID-19 (2478)
CRISPR (35)
C-suite (211)
Cystic fibrosis (81)
Data (1813)
Decentralized trials (2)
Denatured (9)
Depression (45)
Diabetes (230)
Diagnostics (5745)
Digital health (13)
Diversity (4)
Diversity, equity & inclusion (38)
Drug discovery (102)
Drug pricing (95)
Drug shortages (24)
Duchenne muscular dystrophy (82)
Earnings (55354)
Editorial (34)
Employer branding (18)
Employer resources (128)
Events (76128)
Executive appointments (623)
FDA (14656)
Featured Employer (23)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (6)
Funding (614)
Gene editing (92)
Generative AI (18)
Gene therapy (268)
GLP-1 (675)
Government (4119)
Grass and pollen (3)
Guidances (45)
Healthcare (16122)
Huntington's disease (23)
IgA nephropathy (23)
Immunology and inflammation (111)
Indications (24)
Infectious disease (2608)
Inflammatory bowel disease (122)
Inflation Reduction Act (11)
Influenza (44)
Intellectual property (78)
Interviews (527)
IPO (12714)
IRA (46)
Job creations (2638)
Job search strategy (1687)
Kidney cancer (10)
Labor market (16)
Layoffs (410)
Leadership (19)
Legal (5798)
Liver cancer (68)
Lung cancer (286)
Lymphoma (121)
Machine learning (2)
Management (51)
Manufacturing (226)
MASH (66)
Medical device (10589)
Medtech (10593)
Mergers & acquisitions (15779)
Metabolic disorders (608)
Multiple sclerosis (67)
NASH (23)
Neurodegenerative disease (88)
Neuropsychiatric disorders (28)
Neuroscience (1838)
NextGen: Class of 2025 (5570)
Non-profit (4013)
Northern California (2020)
Now hiring (29)
Obesity (323)
Opinion (212)
Ovarian cancer (69)
Pain (77)
Pancreatic cancer (72)
Parkinson's disease (126)
Partnered (15)
Patents (189)
Patient recruitment (89)
Peanut (40)
People (51076)
Pharmaceutical (26)
Pharmacy benefit managers (10)
Phase I (18329)
Phase II (26156)
Phase III (19941)
Pipeline (934)
Podcasts (44)
Policy (106)
Postmarket research (2322)
Preclinical (7492)
Press Release (55)
Prostate cancer (83)
Psychedelics (37)
Radiopharmaceuticals (210)
Rare diseases (333)
Real estate (4221)
Recruiting (56)
Regulatory (19127)
Reports (25)
Research institute (2138)
Resumes & cover letters (359)
Rett syndrome (3)
RNA editing (2)
RSV (35)
Schizophrenia (68)
Series A (108)
Series B (71)
Service/supplier (5)
Sickle cell disease (48)
Southern California (1783)
Special edition (10)
Spinal muscular atrophy (145)
Sponsored (27)
Startups (2837)
State (2)
Stomach cancer (13)
Supply chain (50)
The Weekly (33)
United States (17357)
Vaccines (606)
Venture capitalists (30)
Webinars (11)
Weight loss (225)
Women's health (24)
Worklife (16)
Date
Today (110)
Last 7 days (513)
Last 30 days (2395)
Last 365 days (29386)
2025 (6654)
2024 (30771)
2023 (34583)
2022 (45117)
2021 (48435)
2020 (46818)
2019 (39962)
2018 (30295)
2017 (27280)
2016 (26035)
2015 (30341)
2014 (22852)
2013 (18612)
2012 (20017)
2011 (20966)
2010 (18561)
Location
Africa (734)
Alabama (44)
Alaska (4)
Arizona (148)
Arkansas (11)
Asia (33822)
Australia (7073)
California (4596)
Canada (1664)
China (419)
Colorado (206)
Connecticut (195)
Delaware (110)
Europe (75374)
Florida (719)
Georgia (158)
Idaho (50)
Illinois (419)
India (21)
Indiana (260)
Iowa (5)
Japan (129)
Kansas (91)
Kentucky (18)
Louisiana (6)
Maine (48)
Maryland (725)
Massachusetts (3188)
Michigan (184)
Minnesota (273)
Mississippi (1)
Missouri (68)
Montana (20)
Nebraska (22)
Nevada (50)
New Hampshire (63)
New Jersey (1336)
New Mexico (20)
New York (1312)
North Carolina (756)
North Dakota (5)
Northern California (2020)
Ohio (157)
Oklahoma (5)
Oregon (26)
Pennsylvania (1008)
Puerto Rico (9)
Rhode Island (21)
South America (999)
South Carolina (15)
South Dakota (1)
Southern California (1783)
Tennessee (72)
Texas (698)
Utah (150)
Virginia (115)
Washington D.C. (47)
Washington State (437)
West Virginia (3)
Wisconsin (36)
550,200 Results for "celyad formally known as cardio3 biosciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Celyad Oncology announces intention to terminate SEC reporting obligations
Celyad Oncology SA announces that it will voluntarily file a Form 15F with the United States Securities and Exchange Commission to terminate its SEC reporting obligations under Section 13 or Section 15 of the Securities Exchange Act of 1934, as amended.
February 8, 2024
·
4 min read
Business
Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook
Celyad Oncology (Euronext: CYAD) (the “Company”), today provides a fourth quarter 2023 business update and an outlook for 2024.
January 16, 2024
·
7 min read
Business
Celyad announces management change - December 04, 2023
Celyad Oncology announces that its CEO and managing director Georges Rawadi has decided to step down, effective as of Friday December 1, 2023.
December 4, 2023
·
3 min read
Press Releases
Celltrion’s Remdantry™, previously known as Inflectra®, will be available in Canada as of April 1, 2025
March 27, 2025
·
3 min read
Drug Development
Saghmos Therapeutics Announces Collaboration with Duke Clinical Research Institute to Optimize Phase 3 Cardio-Renal Metabolic Study
Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company, announced it will partner with the Duke Clinical Research Institute (DCRI) to optimize all aspects of and plan the operationalization of Saghmos’ Phase 3 study for its cardio-renal metabolic modulator ST-62516.
April 17, 2024
·
4 min read
Press Releases
Know Labs Technology Licensing (KTL) Announces Formalized Client Engagement
February 6, 2025
·
7 min read
Press Releases
CB Scientific Inc. (CBSC) Formally Launches Next Generation MyCardia AT Cardiac Monitor
February 25, 2025
·
4 min read
Business
Celyad Oncology reports third quarter 2023 financial results and recent business highlights
Celyad Oncology, a biotechnology company focused on innovative technologies for chimeric antigen receptor T-cell therapies, reports its financial results for the third quarter of 2023 and provides an update on recent business developments.
November 9, 2023
·
9 min read
Celyad Oncology announces the termination of its American Depository Receipt program
Celyad Oncology SA announces that Citibank, N.A., as depositary, shall issue the notice of terminating its American Depository Receipt program of American Depositary Shares representing ordinary shares to the holders of ADSs according to the requirements under the deposit agreement.
September 25, 2023
·
4 min read
Celyad Oncology Reports First Half 2023 Financial Results and Recent Business Highlights
Celyad Oncology, announces its financial results and recent business developments for the first half year, ended June 30, 2023.
September 4, 2023
·
14 min read
1 of 55,020
Next
